Skip to main content

Table 4 Prognostic factors for overall survival (OS), univariate and multivariate analyses

From: Associations of muscle and adipose tissue parameters with long-term outcomes in middle and low rectal cancer: a retrospective cohort study

Prognostic factor

Univariate

Multivariate

HR (95% CI)

P

HR (95% CI)

P

Age (years)

0.983(0.952–1.015)

0.301

  

Sex

0.505(0.214–1.189)

0.118

  

BMI (kg/m2)

0.873(0.747–1.020)

0.087*

0.864(0.745–1.002)

0.054

CEA (ng/mL)

1.011(0.995–1.027)

0.191

  

TNM stage

 

0.304

  

I

Reference

Reference

  

II

1.650(0.333–8.175)

0.540

  

III

2.147(0.470–9.801)

0.324

  

IV

5.351(0.893–32.044)

0.066

  

Complications

 

0.035*

 

0.042*

None

Reference

Reference

Reference

Reference

Minor

1.939(0.652–5.770)

0.234

1.825(0.607–5.487)

0.284

Major

3.884(1.408–10.716)

0.009

3.792(1.366–10.525)

0.010

ASA grade

 

0.490

  

1

Reference

Reference

  

2

0.605(0.230–1.590)

0.308

  

3

1.118(0.351–3.564)

0.851

  

Per-op CCRTx

0.037(0.000–4.974)

0.188

  

Post-op CCRTx

0.583(0.242–1.407)

0.230

  

Low-VFA vs high-VFA

1.328(0.560–3.152)

0.520

  

Low-MFA vs high-MFA

0.877(0.372–2.065)

0.764

  

Low-SMI vs high-SMI

2.673(1.037–6.890)

0.042*

2.776(1.071–7.196)

0.036*

Low-SMD vs high-SMD

2.745(1.065–7.077)

0.037*

3.058(1.178–7.941)

0.022*

  1. *Significant P values
  2. For risk factors with more than 2 categories, the first category was considered as the reference group
  3. ASA American Society of Anesthesiologists, BMI body mass index, CCRTx chemoradiation therapy, CEA carcinoembryonic antigen, MFA area of mesorectal fat, SMD skeletal muscle radiodensity, SMI skeletal muscle index, TNM tumor-node-metastasis, VFA area of visceral fat